Literature DB >> 17555444

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Alberto Orfao1, Andrés C Garcia-Montero, Laura Sanchez, Luis Escribano.   

Abstract

Mastocytosis is a heterogeneous disorder characterised by the expansion and accumulation of mast cells in different organs and tissues. Mast cell physiology is closely dependent on activation of the stem cell factor/Kit signalling pathways and accumulating evidences confirm the physiopathological key role of activating KIT mutations (typically D816V) in mastocytosis and their relationship with the clinical manifestations of the disease. This paper reviews the most recent advances in the understanding of the molecular mechanisms associated with KIT mutations in mastocytosis, including recent data about the use of new therapies targeting the Kit molecule and its associated downstream signalling pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555444     DOI: 10.1111/j.1365-2141.2007.06619.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  62 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

Review 2.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

3.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

4.  CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.

Authors:  Martin Schmidt-Hieber; Martin Pérez-Andrés; Bruno Paiva; Juan Flores-Montero; Jose J Perez; Norma C Gutierrez; Maria-Belen Vidriales; Sergio Matarraz; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

5.  The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.

Authors:  Jianmin Sun; Malin Pedersen; Lars Rönnstrand
Journal:  J Biol Chem       Date:  2009-03-05       Impact factor: 5.157

6.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

Authors:  Thomas Kristensen; Hanne Vestergaard; Michael Boe Møller
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

7.  Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.

Authors:  A Mayado; C Teodosio; A C Garcia-Montero; A Matito; A Rodriguez-Caballero; J M Morgado; C Muñiz; M Jara-Acevedo; I Álvarez-Twose; L Sanchez-Muñoz; S Matarraz; C Caldas; J I Muñoz-González; L Escribano; A Orfao
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

8.  A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Authors:  Jean-Emmanuel Kurtz; Irène Asmane; Anne-Claire Voegeli; Agnès Neuville; Armelle Dufresne; Valère Litique; Christine Chevreau; Jean-Pierre Bergerat
Journal:  Sarcoma       Date:  2010-03-17

9.  Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Authors:  Patrice Dubreuil; Sébastien Letard; Marco Ciufolini; Laurent Gros; Martine Humbert; Nathalie Castéran; Laurence Borge; Bérengère Hajem; Anne Lermet; Wolfgang Sippl; Edwige Voisset; Michel Arock; Christian Auclair; Phillip S Leventhal; Colin D Mansfield; Alain Moussy; Olivier Hermine
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

10.  Selective RNAi-mediated inhibition of mutated c-kit.

Authors:  Irene Ruano; Marta Izquierdo
Journal:  J RNAi Gene Silencing       Date:  2009-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.